Cempra to Report First Quarter 2017 Financial Results
April 13 2017 - 7:00AM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing differentiated anti-infectives for acute care
and community settings to meet critical medical needs in the
treatment of infectious diseases, today announced that it will
report first quarter 2017 financial results before the opening of
U.S. financial markets on Friday, April 28, 2017. Cempra management
will host a webcast and conference call at 8:45 a.m. ET that day to
discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-377-7553 for
domestic callers and 253-237-1151 for international callers and
using conference ID # 99531916. A live webcast of the call will be
available online from the investor relations section of the company
website at www.cempra.com and will be archived there for 30 days. A
telephone replay of the call will be available by dialing
855-859-2056 for domestic callers or 404-537-3406 for international
callers and entering the conference ID # 99531916.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused
on developing differentiated anti-infectives for acute care and
community settings to meet critical medical needs in the treatment
of infectious diseases. Cempra's two lead product candidates are
currently in advanced clinical development. Solithromycin has been
evaluated in two phase 3 clinical trials for community-acquired
bacterial pneumonia (CABP). Cempra is currently seeking approval
for CABP for both intravenous and oral capsule formulations from
the U.S. Food and Drug Administration. Solithromycin is licensed to
strategic commercial partner Toyama Chemical Co., Ltd., a
subsidiary of FUJIFILM Holdings Corporation, for certain exclusive
rights in Japan. Cempra is contracted with BARDA for the
development of solithromycin for pediatric use and has commenced
enrollment in a global Phase 2/3 trial to evaluate the safety and
efficacy of solithromycin versus standard of care antibiotics in
children and adolescents from two months to 17 years of age.
Solithromycin is also in development for uncomplicated urogenital
urethritis caused by Neisseria gonorrhoeae or chlamydia. Fusidic
acid is Cempra's second product candidate, which has completed a
phase 3 trial comparing fusidic acid to linezolid in patients with
acute bacterial skin and skin structure infections (ABSSSI). Cempra
also has an ongoing exploratory study of fusidic acid for chronic
oral treatment of refractory infections in bones and joints. Both
products seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the
community. Cempra is also studying solithromycin for ophthalmic
conditions and has synthesized novel macrolides for non-antibiotic
uses such as the treatment of chronic inflammatory diseases,
endocrine diseases and gastric motility disorders. Cempra was
founded in 2006 and is headquartered in Chapel Hill, N.C. For
additional information about Cempra please visit
www.cempra.com.
Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024